481 related articles for article (PubMed ID: 31191013)
1. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
Inokuchi J; Eto M
Cancer Manag Res; 2019; 11():4519-4528. PubMed ID: 31191013
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
[TBL] [Abstract][Full Text] [Related]
4. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
5. Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.
Nabar ND; Brandt MP; Thomas C; Tsaur I; Bartsch G; Jaeger W; Haferkamp A; Höfner T
Minerva Urol Nefrol; 2019 Jun; 71(3):205-216. PubMed ID: 30021426
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
Lopez-Beltran A; Cimadamore A; Blanca A; Massari F; Vau N; Scarpelli M; Cheng L; Montironi R
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401585
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
Gwynn ME; DeRemer DL
Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
[TBL] [Abstract][Full Text] [Related]
8. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
Ghatalia P; Zibelman M; Geynisman DM; Plimack E
Ther Adv Med Oncol; 2018; 10():1758835918788310. PubMed ID: 30083254
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
10. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
11. Management of metastatic bladder cancer.
Nadal R; Bellmunt J
Cancer Treat Rev; 2019 Jun; 76():10-21. PubMed ID: 31030123
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
13. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer.
Resch I; Shariat SF; Gust KM
Memo; 2018; 11(1):43-46. PubMed ID: 29606979
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.
Seront E; Catala G; Dermine A; Lejeune S; Rysselinck S
Future Sci OA; 2018 Dec; 4(10):FSO341. PubMed ID: 30457576
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
17. Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review.
Kim TJ; Cho KS; Koo KC
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31940998
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
19. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
